-

Click Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced that Randall Stanicky, Chief Financial Officer, will present at the 22nd Annual Needham Virtual Healthcare Conference on Monday, April 17, 2023 at 2:15 p.m. ET.

Company management will also participate in one-on-one meetings during the conference, which will be held virtually on April 17-20, 2023.

About Click Therapeutics

Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for patients with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes. Click is progressing a broad pipeline of Digital Therapeutics™ across a variety of high-burden therapeutic areas, including Major Depressive Disorder, Schizophrenia, Migraine, Multiple Sclerosis, Chronic Pain, Atopic Dermatitis, Acute Coronary Syndrome, Obesity, Oncology and more. For more information on Click, visit ClickTherapeutics.com.

Contacts

Investor Contact
Daniel Busby
ir@clicktherapeutics.com

Media Contact
Jonni Mills
pr@clicktherapeutics.com

Click Therapeutics, Inc.


Release Summary
Click Therapeutics announced that Randall Stanicky, Chief Financial Officer, will present at the 22nd Annual Needham Virtual Healthcare Conference.
Release Versions

Contacts

Investor Contact
Daniel Busby
ir@clicktherapeutics.com

Media Contact
Jonni Mills
pr@clicktherapeutics.com

More News From Click Therapeutics, Inc.

Click Therapeutics Announces FDA Marketing Authorization for CT-132, the First Prescription Digital Therapeutic for the Preventive Treatment of Episodic Migraine in the United States

NEW YORK--(BUSINESS WIRE)--Click Therapeutics Announces FDA Marketing Authorization for CT-132, the First PDT for the Preventive Treatment of Episodic Migraine in the U.S....

Click Therapeutics Underscores Its Commitment to Innovation and Leadership in Software as Prescription Medical Treatments with Launch of New Brand Identity

NEW YORK--(BUSINESS WIRE)--Click Therapeutics Underscores Its Commitment to Innovation and Leadership in Software as Prescription Medical Treatments with New Brand Identity...

Click Therapeutics Launches Software-Enhanced Drug™ Therapies as Part of New Click SE™ Offering

NEW YORK--(BUSINESS WIRE)--Click Therapeutics Launches Software-Enhanced Drug™ Therapies as part of new Click SE™ Offering....
Back to Newsroom